Retrophin to Present at the 15th Annual BIO CEO & Investor Conference
Retrophin to Present at the 15thAnnual BIO CEO & Investor Conference
Clinical and corporate updates to be shared February 12 at 3:30 p.m.
NEW YORK--(BUSINESS WIRE)-- Retrophin (OTCQB: RTRX), a biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases, today announced that Martin Shkreli, Founder & Chief Executive Officer, will be presenting at the 15th Annual BIO CEO & Investor Conference, which is being held February 11-12 in New York, NY. Shkreli will provide corporate updates and discuss upcoming clinical milestones, including enrollment in a potentially pivotal Phase II clinical trial of Retrophin's lead compound, RE-021.
Details of the presentation are as follows:
Date: | Tuesday, February 12 | ||||||
Time: | 3:30 p.m. ET | ||||||
Location: | The Waldorf Astoria New York |
A webcast of the presentation will be available on Retrophin's web site: http://www.retrophin.com/.
About Retrophin
Retrophin is a biotechnology company focused on discovering and developing treatments for rare and life-threatening diseases. Retrophin is currently developing treatments for focal segmental glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. The company's lead compound, RE-021, formerly known as DARA, is scheduled to begin enrollment in a potentially pivotal Phase II clinical trial for FSGS in the first half of 2013.
Retrophin Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Retrophin's business. Retrophin undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Retrophin, Inc.
Martin Shkreli, CEO
212-983-1310
martin.shkreli@retrophin.com
or
6 Degrees
Annie Starr (Media)
973-415-8838
astarr@6degreespr.com
or
Rx Communications Group
Paula Schwartz (Investors)
917-322-2216
pschwartz@rxir.com
KEYWORDS: United States North America New York
INDUSTRY KEYWORDS:
The article Retrophin to Present at the 15th Annual BIO CEO & Investor Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
